Penalty Amount
$300,000
Connecticut Attorney General William Tong announced a settlement with international trade platform Made-in-China to cease all U.S. sales of unlawful 'research grade' GLP-1 weight loss drugs following an investigation into direct sales to consumers without prescriptions or medical oversight. The settlement prohibits the platform from hosting GLP-1 sales to U.S. customers, requires a monitoring system to remove non-compliant listings, and imposes a $300,000 penalty suspended after an initial $30,000 payment. Additional settlements were announced with Radiance Medspa and Advanced Medical Weight Loss over compounded non-FDA approved GLP-1 drugs.
Made-in-China must prohibit manufacturers from advertising or selling GLP-1s to U.S. customers, deploy a monitoring system to detect and remove such listings, and remove existing GLP-1 listings within five days. The company is subject to a $300,000 penalty, with $30,000 due initially and the remaining $270,000 suspended; additional penalties apply for settlement violations.
In-house legal teams at online trade platforms and e-commerce vendors should review vendor agreements and terms of service to add explicit prohibitions on selling unapproved FDA-regulated drugs, prescription-only medications, and misbranded health products without valid medical oversight. Contracts should include requirements for automated monitoring systems to detect non-compliant listings, specified timeframes for removing prohibited content, and penalty clauses with suspended amounts that trigger upon breach of terms. Platforms should also include indemnification provisions and audit rights to ensure vendor compliance with health and safety regulations.
Entity
Made-in-China
Industry
Other"05/06/2026"
"Made-in-China"
"$300,000 penalty to the state, suspended after $30,000"
"violations of the Connecticut Unfair Trade Practices Act"
"unlawful sales of bootleg GLP-1 weight loss drugs direct to Connecticut consumers without prescriptions or any medical oversight"
"prohibits manufacturers from using the platform to advertise or sell GLP-1s to customers in the United States"
$625K
Connecticut reached a $625,000 settlement with Frontier Communications Parent Inc. over an April 2024 breach in which compromised employee and vendor credentials were used to access internal systems and exfiltrate unencrypted personal information of 58,841 Connecticut residents. The settlement requires Frontier to strengthen its security program, implement specific safeguards and training, and obtain an independent third-party assessment.
$2.6M
Connecticut and New York found that Boston Children’s Health Physicians and its security vendor, XTIUM, failed to use reasonable safeguards, resulting in hackers accessing sensitive personal, medical, and employee information. The companies agreed to pay penalties totaling $2.64 million and implement enhanced cybersecurity measures.
Connecticut joined a coalition of state attorneys general filing a notice in Character Technologies, Inc.’s bankruptcy proceedings, raising concerns about the company’s safety and privacy practices and the sensitive information it holds. The states seek protections for children and consumers if the company’s business or assets are sold or transferred; the filing does not impose a fine or other remedy.
Attorney General William Tong and Consumer Counsel Claire Coleman petitioned PURA to review how Connecticut public utilities use artificial intelligence, citing potential data privacy and cybersecurity risks, algorithmic errors, and misleading outputs. The petition asks PURA to examine utility AI systems, safeguards, vendors, and data security practices; it does not report a finding of violation or an imposed penalty.
$2.0M
Connecticut Attorney General William Tong announced a settlement with RZ Smoke, Inc. over allegations that it distributed and sold high-potency cannabis products without a state license. The stipulated judgment is $2 million, with $375,000 payable to the State and $1.6 million suspended to ensure compliance; the company is barred from specified cannabis activities in Connecticut unless licensed.
$13.7M
Connecticut joined a coalition of states and the federal government in settling allegations that Takeda paid healthcare providers speaker honoraria and provided meals to induce prescriptions of Trintellix, leading to allegedly false claims to government healthcare programs. Takeda agreed to pay $13,670,921 plus accrued interest, with portions allocated to federal and state programs.